2011.11.28 Weekly Broadcast Email
The following updates were made to the CCCWF CCOP Research Base website for the week of November 28, 2011.
97609(Impact of Genomics and Exposures on Disparities in Breast Cancer Radiosensitivity)
Amendment 2 has been added to the website. This amendment includes changes to the protocol, consent and appendices.
Please note: Lab specimen information should be entered into CCRBIS. This will assist the lab technicians in linking received specimens with patient identifiers.
91105 (Phase III Double Blind, Placebo Controlled Study of Donepezil in Irradiated Brain Tumor Patients)
Announcement from study PI:
91105 is nearing completion of enrollment with 197 of 200 participants enrolled. We still need 3 additional enrollments to reach our goal, however. Please try to help us reach our goal by December. This study will be closed to enrollment at the end of this month. Also, please send in the MRIs as soon as possible so we can process your reimbursement. Thanks!!
Steve Rapp, PhD, PI
The following adverse events were received during the month of November. They have been attached to this email and summarized on the Adverse Event webpage.
97509: 14 and 15
During the month of November, 40 patients were accrued to CCCWFU CCOP Research Base trials. Congratulations to the Wichita CCOP for accruing the most patients. See the Research Base website spotlight section for further information.
97106(A Randomized Study to Determine whether ArginMax Improves the Sexual Function and Quality of Life in Female Cancer Survivors)
The 2011 WFU Continuing Review Approval letter has been added to the website.